Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Lymphatic Metastasis 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Dermatofibrosarcoma 1

Interventions

Temozolomide 18Radiation 7Magnetic Resonance Spectroscopy 7Radiotherapy 6Specimen Handling 4Lomustine 4Bevacizumab 4Aminolevulinic Acid 3veliparib 2trametinib 2lutetium Lu 177 dotatate 2dabrafenib 2azeliragon 2Surgical Procedures, Operative 2Receptors, Interleukin-8B 2Nivolumab 2D2C7-(scdsFv)-PE38KDEL 2Carboplatin 2Biopsy 2varlilumab 1ulixertinib 1tinostamustine 1selinexor 1ruxolitinib 1ribociclib 1relatlimab 1regorafenib 1peposertib 1pembrolizumab 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × peposertib × 30 days × Clear all
NCT04555577 2026-05-20

Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma

M.D. Anderson Cancer Center

Phase 1 Recruiting
29 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡